This is a multicenter, randomized, double-blind, parallel placebo-controlled, phase 3 clinical trial to evaluate the protective efficacy, safety, and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above. 45,000 people will participate in this study.